EUVIMEDEUVIMED entdecken
Open Access

Galectin-3 as a Candidate Marker of Endocrine-modulator-associated Endometrial Remodeling During Breast Cancer Endocrine Therapy

Adamantia Kontogeorgi, Ioannis Boutas, Dimitrios Kalaitzis, Tatiana S Driva, George Agrogiannis, Emmanouil Zoumakis, Sophia N Kalantaridou, Antonios Makrigiannakis

In Vivo · 2026-11 · 40 (6) · 3519-3539

DOI: 10.21873/invivo.14494 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, online erschienen am 29.10.2026. Verfasst von Adamantia Kontogeorgi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, University of Crete, Heraklion, Greece; adamantia.kondogewrgi@gmail.com. Hauptthemen laut MEDLINE: Galectin 3, Endometrium, Antineoplastic Agents, Hormonal, Breast Neoplasms. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Galectin 3EndometriumAntineoplastic Agents, HormonalBreast NeoplasmsFemaleAnimalsRatsHumansTamoxifenMifepristoneBiomarkersCell Line, TumorBiomarkers, TumorImmunohistochemistry

Stichwörter der Autor:innen

Galectin-3antiprogestinsbreast cancerendocrine therapyendometrial hyperplasia

Substanzen

Galectin 3TamoxifenAntineoplastic Agents, HormonalMifepristoneBiomarkersBiomarkers, Tumor

Autor:innen und Institutionen

  • Medical School, University of Crete, Heraklion, Greece; adamantia.kondogewrgi@gmail.com.
  • Breast Unit, Rea Maternity Hospital, Athens, Greece.
  • Independent Authority of Public Revenue, Athens, Greece.
  • 1 Department of Pathology, General Hospital of Athens "Laiko", Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • 1 Department of Propedeutic Surgery, General Hospital of Athens "Laiko", Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • 1 Department of Pediatrics, Medical School, General Hospital of Athens "Agia Sofia", Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Zitieren

APA

Kontogeorgi, A., Boutas, I., Kalaitzis, D., Driva, T. S., Agrogiannis, G., Zoumakis, E., Kalantaridou, S. N., & Makrigiannakis, A. (2026). Galectin-3 as a Candidate Marker of Endocrine-modulator-associated Endometrial Remodeling During Breast Cancer Endocrine Therapy. In Vivo, 40(6), 3519-3539. https://doi.org/10.21873/invivo.14494

Vancouver

Kontogeorgi A, Boutas I, Kalaitzis D, Driva TS, Agrogiannis G, Zoumakis E, et al. Galectin-3 as a Candidate Marker of Endocrine-modulator-associated Endometrial Remodeling During Breast Cancer Endocrine Therapy. In Vivo. 2026;40(6):3519-3539. doi:10.21873/invivo.14494

BibTeX
@article{Kontogeorgi2026,
  author = {Kontogeorgi, Adamantia and Boutas, Ioannis and Kalaitzis, Dimitrios and Driva, Tatiana S and Agrogiannis, George and Zoumakis, Emmanouil and Kalantaridou, Sophia N and Makrigiannakis, Antonios},
  title = {Galectin-3 as a Candidate Marker of Endocrine-modulator-associated Endometrial Remodeling During Breast Cancer Endocrine Therapy},
  journal = {In Vivo},
  year = {2026},
  volume = {40},
  number = {6},
  pages = {3519--3539},
  doi = {10.21873/invivo.14494}
}
Kostenlos starten →